by TractManager | Nov 30, 2015 | Emerging Technology Report
An oral BRAF and MEK inhibitor combination therapy for unresectable or advanced melanoma with BRAF V600E or V600K mutations.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Nov 24, 2015 | Health Technology Assessment
Purpose of Technology Mechanical thrombectomy for acute ischemic stroke involves the use of minimally invasive devices such as stent retrievers that are inserted into the femoral artery in the groin and advanced to the site of the blockage in a cerebral artery. The...
by TractManager | Nov 18, 2015 | Emerging Technology Report
The Superion Interspinous Spacer is an interspinous implant proposed to treat neurogenic claudication in patients with impaired physical function secondary to moderate lumbar spinal stenosis with or without grade 1 spondylolisthesis who have undergone at least 6...
by TractManager | Nov 17, 2015 | Health Technology Assessment
Purpose of Technology For intraoperative radiotherapy (IORT), a single high dose of radiation is given to the tumor bed at the time of breast-conserving surgery in patients with early-stage breast cancer, which has not spread beyond the breast or lymph nodes in the...
by TractManager | Nov 11, 2015 | Emerging Technology Report
Cotellic (cobimetinib) and Zelboraf (vemurafenib) is an oral BRAF and MEK inhibitor combination therapy for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.If you have a Hayes login, click here to view the full report on the...
Recent Comments